Hexapeptide-40
/ Synthetic hexapeptide; INCI 'Hexapeptide-40'; sirtuin-1 (SIRT1) activating cosmetic peptideALIAS · Juvinity (trade) · Hexapeptide-40 (INCI) · Sirtuin-activating hexapeptide
Terms in this page you can click for a plain-English popup: , , , , , , , .
Tier 4 cosmeceutical. INCI catalog peptide marketed under the Juvinity trade name; mechanism positioning is sirtuin-1 (SIRT1) activation in cultured dermal fibroblasts. PubMed-indexed independent primary literature on the cosmetic peptide is essentially absent; supplier materials provide the published narrative.
The supplier-stated mechanism is activation of sirtuin-1 (SIRT1), a NAD+-dependent class III histone deacetylase implicated in cellular stress response, mitochondrial biogenesis, and longevity-associated pathways. The cosmetic positioning extrapolates from systemic SIRT1 activator literature (resveratrol, SRT compounds) to a topical hexapeptide effect on dermal fibroblast aging. Whether a six-residue peptide applied topically engages SIRT1 in human dermal fibroblasts in vivo is not independently established.
None substantive in the indexed primary literature. Supplier in-vitro fibroblast SIRT1-reporter and SIRT1-protein-expression assays are referenced in INCI documentation but not represented as PubMed-indexed peer-reviewed papers for the cosmetic peptide specifically.
No formal human safety database in indexed literature. Topical cosmetic application is generally well tolerated.
Regulatory status
- FDA status:
- Not FDA-approved
The 'sirtuin activator' framing borrows from the systemic geroscience literature on SIRT1 small-molecule activators without independent evidence that the topical hexapeptide engages SIRT1 in human skin. The systemic SIRT1-activator literature itself is methodologically contested (assay-artefact concerns about resveratrol-class activators); the cosmetic peptide claim sits one extrapolation further removed.